Heberprot-P, A Cuban Biotechnology Example to the World

Havana, Apr 2 (Prensa Latina) Heberprot-P has become in the last three years the leader product of the Cuban Center of Genetic Immunology and Biotechnology (CIGB), experts of the sector told the news agency Prensa Latina today.

Doctor Carlos Mella, expert in Market Intelligence of the Marketing Company of Biotechnological and Pharmaceutical Products of the CIGB, Heber-Biotec, said the medicine made the difference at international level.

Heber-Biotec, founded in 1991, is one of the speakers at the 2nd International Conference Technology and Health, with Havana’s Conference Center as venue.

Heberprot-P is used to treat piercing ulcers on diabetic foot, an injury really hard to fight, at the extent that most patients with this injury lose their affected leg.

Mella explained that before having the mentioned medicine, the CIGB worked on other research lines. The closest treatment to skin ulcers was an cream, only for external use that is still produced today, but used for burns and related injuries.

Arts graduate Carmen Marrero, sales manager of the division of European countries at Heber-Biotec, reported to Prensa Latina that Heberprot-P had been already registered in 19 Latin American countries, North Africa and Asia.


Modificado el ( miércoles, 02 de abril de 2014 )

Heberprot-P, a unique drug developed in Cuba for patients with diabetic foot ulcers

Sancti Spiritus Outstanding in Heberprot-P Treatment Actions

Heberprot-P is a unique drug developed in Cuba.

By Arelys García Acosta | Escambray

Over 70 per cent of diabetic foot ulcer cases in Sancti Spiritus are handled at primary-health-care institutions, where Heberprot-P treatment is possible.

The abovementioned statement was made known during a meeting held this Friday in this city, where experts from all over the island discussed how to systematize early actions involving diabetic patients.

Rafael Ibargollin Ulloa, coordinator of the National Program for the Extension of Heberprot-P in central Cuba, emphasized the convenience of treating ulcerations in early stages; this way patients heal sooner, and subsequent complications can be prevented.

Over 300 diabetic patients have been so far diagnosed in Sancti Spiritus this year. This territory outstands in the Heberprot-B-related program implementation, and is only preceded by Isla de la Juventud.

Some 20 626 diabetic foot ulcer patients have been treated in hospitals, polyclinics, and diabetic people assistance centers, since  the drug was first used at primary health care level in the island.

(Translated by Escambray)